MR-MAPs initial Full Vaccine Value Assessment

In partnership with the London School of Hygiene and Tropical Medicine and Global Health Visions, support the development of an initial Full Vaccine Value Assessment of Measles-Rubella micro-array patches (MR-MAPs), including conducting a quantitative assessment of the public health needs and how MR-MAPs can address those public health needs; conducting market analyses, including pricing assessment, discounted cash flow assessment; and estimating the impact and cost-effectiveness of MR-MAPs.